Katy White

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B. Gordon, Peter Foley, James G. Krueger et al. · The Lancet · 2021 · 284 citations

Medicine, Dermatology, Pharmacology +6

Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.

G Chouinard, Wayne K. Goodman, John H. Greist et al. · PubMed · 1990 · 136 citations

Medicine, Pharmacology, Pharmacotherapy +11

A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder

John H. Greist, James W. Jefferson, Kenneth A. Kobak et al. · International Clinical Psychopharmacology · 1995 · 132 citations

Medicine, Pharmacotherapy, Psychiatry +13

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Bruce Strober, C. Paul, Andrew Blauvelt et al. · Journal of the American Academy of Dermatology · 2023 · 40 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials

Matthew A. Brown, Martín Rudwaleit, F. van Gaalen et al. · Annals of the Rheumatic Diseases · 2024 · 33 citations · Full text

Medicine, Immunology, Pharmacotherapy +16